Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
7893 | 1239 | 44.9 | 92% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
157 | 21931 | BENIGN PROSTATIC HYPERPLASIA//PROSTATE CANCER//PROSTATE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | PCA3 | Author keyword | 129 | 85% | 5% | 68 |
2 | TMPRSS2 ERG | Author keyword | 76 | 86% | 3% | 38 |
3 | PROSTATE CANCER ANTIGEN 3 | Author keyword | 73 | 96% | 2% | 23 |
4 | PROSTATE CANCER GENE 3 | Author keyword | 31 | 92% | 1% | 12 |
5 | TMPRSS2 | Author keyword | 28 | 64% | 2% | 27 |
6 | PROSTATE CANCER ANTIGEN 3 HUMAN | Author keyword | 27 | 92% | 1% | 11 |
7 | TMPRSS2ERG | Author keyword | 24 | 82% | 1% | 14 |
8 | TMPRSS2 ERG FUSION | Author keyword | 23 | 86% | 1% | 12 |
9 | ERG | Author keyword | 19 | 18% | 8% | 94 |
10 | ERG REARRANGEMENT | Author keyword | 17 | 100% | 1% | 8 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PCA3 | 129 | 85% | 5% | 68 | Search PCA3 | Search PCA3 |
2 | TMPRSS2 ERG | 76 | 86% | 3% | 38 | Search TMPRSS2+ERG | Search TMPRSS2+ERG |
3 | PROSTATE CANCER ANTIGEN 3 | 73 | 96% | 2% | 23 | Search PROSTATE+CANCER+ANTIGEN+3 | Search PROSTATE+CANCER+ANTIGEN+3 |
4 | PROSTATE CANCER GENE 3 | 31 | 92% | 1% | 12 | Search PROSTATE+CANCER+GENE+3 | Search PROSTATE+CANCER+GENE+3 |
5 | TMPRSS2 | 28 | 64% | 2% | 27 | Search TMPRSS2 | Search TMPRSS2 |
6 | PROSTATE CANCER ANTIGEN 3 HUMAN | 27 | 92% | 1% | 11 | Search PROSTATE+CANCER+ANTIGEN+3++HUMAN | Search PROSTATE+CANCER+ANTIGEN+3++HUMAN |
7 | TMPRSS2ERG | 24 | 82% | 1% | 14 | Search TMPRSS2ERG | Search TMPRSS2ERG |
8 | TMPRSS2 ERG FUSION | 23 | 86% | 1% | 12 | Search TMPRSS2+ERG+FUSION | Search TMPRSS2+ERG+FUSION |
9 | ERG | 19 | 18% | 8% | 94 | Search ERG | Search ERG |
10 | ERG REARRANGEMENT | 17 | 100% | 1% | 8 | Search ERG+REARRANGEMENT | Search ERG+REARRANGEMENT |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TMPRSS2 ERG FUSION | 104 | 82% | 5% | 60 |
2 | TMPRSS2 ERG GENE FUSION | 95 | 78% | 5% | 63 |
3 | DD3PCA3 | 79 | 88% | 3% | 37 |
4 | MOLECULAR URINE ASSAY | 68 | 70% | 5% | 57 |
5 | TMPRSS2 ERG | 66 | 83% | 3% | 38 |
6 | DNA BASED DETECTION | 64 | 82% | 3% | 37 |
7 | PCA3 | 57 | 70% | 4% | 48 |
8 | DD3 | 48 | 91% | 2% | 20 |
9 | PSA RECURRENCE | 38 | 76% | 2% | 26 |
10 | TMPRSS2 ERG FUSION TRANSCRIPTS | 36 | 65% | 3% | 34 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer | 2015 | 3 | 68 | 46% |
The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications | 2015 | 2 | 42 | 62% |
Common Gene Rearrangements in Prostate Cancer | 2011 | 93 | 75 | 69% |
Molecular Diagnosis of Prostate Cancer: PCA3 and TMPRSS2:ERG Gene Fusion | 2012 | 40 | 46 | 83% |
The Mutational Landscape of Prostate Cancer | 2013 | 35 | 66 | 59% |
The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature | 2014 | 4 | 80 | 99% |
ETS gene fusions in prostate cancer | 2009 | 115 | 76 | 64% |
ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice | 2009 | 107 | 79 | 67% |
Recurrent gene fusions in prostate cancer | 2008 | 298 | 95 | 41% |
Clinical use of novel urine and blood based prostate cancer biomarkers: A review | 2014 | 9 | 73 | 56% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MICHIGAN TRANSLAT PATHOL | 17 | 27% | 4.3% | 53 |
2 | SECT TRANSLAT PROSTATE CANC | 15 | 50% | 1.7% | 21 |
3 | MARTINI CLIN PROSTATE CANC | 6 | 36% | 1.1% | 14 |
4 | PROSTATE CANC | 6 | 11% | 3.9% | 48 |
5 | GEN VISCERAL THORAC SURG CLIN | 5 | 43% | 0.7% | 9 |
6 | SERV BIOCHIM BIOL MOL SUD | 5 | 63% | 0.4% | 5 |
7 | MARTINI CLIN | 4 | 12% | 2.7% | 34 |
8 | GRP CANC GENET | 4 | 75% | 0.2% | 3 |
9 | MED UNIT MOL ONCOL TRANSFER | 4 | 75% | 0.2% | 3 |
10 | PROSTATE DIS | 4 | 11% | 2.4% | 30 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000181611 | DIFFERENTIAL GENE EXPRESSION DETECTION//CANCER OUTLIER PROFILE ANALYSIS//BREAST CANC DIAG TREATMENT HENAN |
2 | 0.0000130779 | PROSTATIC INTRAEPITHELIAL NEOPLASIA//ATYPICAL SMALL ACINAR PROLIFERATION//ALPHA METHYLACYL COA RACEMASE |
3 | 0.0000109228 | NKX31//LOBUND//3 2 DIMETHYL 4 AMINOBIPHENYL |
4 | 0.0000101081 | NORPEG//N COPINE//PSGR |
5 | 0.0000100575 | LZTS1//UROGENE//NUCLEAR ROUNDNESS |
6 | 0.0000099400 | ACTIVE SURVEILLANCE//WATCHFUL WAITING//PROSTATE SPECIFIC ANTIGEN |
7 | 0.0000089921 | RNASEL//HEREDITARY PROSTATE CANCER//8Q24 |
8 | 0.0000070173 | SPLICED LEADER//TRANS SPLICING//CIRCULAR RNA |
9 | 0.0000068635 | PROSTATE SPECIFIC ANTIGEN//FREE PSA//FREE PROSTATE SPECIFIC ANTIGEN |
10 | 0.0000062001 | RRBS//CPG ISLANDS//METHYLTRANSFERASE ACTIVITY |